Compare SpaceX (SPCX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs BIO-TECHNE Corp — how do they compare? SpaceX trades at $132.79 (market cap $1.83T), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: SpaceX is far larger — about 162.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| SPCX | TECH | |
|---|---|---|
Market Cap | $1.83T | $11.24B |
Sector | Technology | Health |
52-Week High | $202.09 | $72.29 |
52-Week Low | $108.27 | $43.31 |
Enterprise Value | $1.77T | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SpaceX (SPCX) trades at $133.11, up 15.83% in 24 hours, reclaiming its $135 IPO price amid bullish technical signals and positive analyst sentiment. The stock shows strong momentum with resistance near $140 and support at $121. Despite negative profitability margins and high valuation ratios, robust revenue growth and significant capital investments in AI and infrastructure signal long-term ambition. Recent news highlights a major chip plant investment and a new satellite launch contract, fueling investor optimism.
Outlook is cautiously optimistic with a consensus price target of $228.52, though risks include persistent losses, high capex, and competitive pressures. The stock offers growth potential driven by Starlink's performance and strategic expansions, but investors must weigh volatility and execution risks against bullish analyst coverage.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
